Clinical trial
Characterization of the Melanoma-Specific Immune Response
NCT00368615 · University of California, Davis, Other · Unknown status
Key facts
| NCT number | NCT00368615 |
|---|---|
| Title | Characterization of the Melanoma-Specific Immune Response |
| Official title | Characterization of the Melanoma-Specific Immune Response |
| Acronym | Melanoma |
| Lead sponsor | University of California, Davis, Other |
| Status | Unknown status |
| Study type | Observational |
| Conditions | Melanoma |
| Enrollment | 20 |
| Start date | Aug 1, 2007 |
| Primary completion | Aug 1, 2024 |
| Completion | Aug 1, 2024 |
| First posted | Aug 25, 2006 |
| Last update posted | Jan 23, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: